StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.03 on Wednesday. The firm has a market capitalization of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68. The stock has a 50-day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.78.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.